NASDAQ:INVO INVO Bioscience (INVO) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free INVO Stock Alerts $0.98 -0.19 (-16.24%) (As of 05:32 PM ET) Add Compare Share Share Today's Range$0.89▼$1.1550-Day Range$0.77▼$1.8252-Week Range$0.50▼$10.50Volume603,651 shsAverage Volume3.02 million shsMarket Capitalization$2.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get INVO Bioscience alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About INVO Bioscience Stock (NASDAQ:INVO)INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.Read More INVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVO Stock News HeadlinesApril 24, 2024 | finance.yahoo.comINVO Bioscience, Inc. (INVO) Stock Price, News, Quote & History - Yahoo FinanceApril 17, 2024 | msn.comMicro Cap Massively Bid Up Before Opening BellApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 17, 2024 | benzinga.comWhy Invo BioScience Stock Is Soaring TodayApril 17, 2024 | msn.comWhy Is Invo Bioscience (INVO) Stock Up 85% Today?April 17, 2024 | investorplace.comWhy Is Invo Bioscience (INVO) Stock Up 85% Today?April 17, 2024 | benzinga.comWhy INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving PremarketApril 17, 2024 | finance.yahoo.comAadi Bioscience, Inc. (AADI) Latest Stock News & Headlines - Yahoo FinanceApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 16, 2024 | msn.comINVO Stock Earnings: INVO Bioscience Reported Results for Q4 2023April 16, 2024 | finance.yahoo.comINVO Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 16, 2024 | americanbankingnews.comShort Interest in INVO Bioscience, Inc. (NASDAQ:INVO) Expands By 10.0%April 4, 2024 | seekingalpha.comASMB Assembly Biosciences, Inc.February 22, 2024 | benzinga.comINVO Bioscience Stock (NASDAQ:INVO), Short Interest ReportFebruary 4, 2024 | morningstar.comINVO Bioscience Inc INVOJanuary 23, 2024 | marketwatch.comINVO BioScience Shares Up 5% as NAYA Agrees to Buy Florida BiotechnologiesJanuary 23, 2024 | finance.yahoo.comNAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)January 23, 2024 | finance.yahoo.comNAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)January 17, 2024 | finance.yahoo.comINVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board DirectorsDecember 23, 2023 | finance.yahoo.comINVO Bioscience, Inc. (INVO) Stock Historical Prices & Data - Yahoo FinanceDecember 11, 2023 | finance.yahoo.comNAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood JournalDecember 6, 2023 | msn.comNAYA, ONK team up to evaluate potential cancer therapy combinationsDecember 6, 2023 | finance.yahoo.comNAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell TherapiesNovember 28, 2023 | finance.yahoo.comINVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNovember 14, 2023 | benzinga.comWhy INVO Bioscience Shares Are Trading Higher By Over 31%; Here Are 20 Stocks Moving PremarketNovember 13, 2023 | finance.yahoo.comINVO Reports Record Third Quarter 2023 Financial ResultsNovember 13, 2023 | msn.comWhat's Going On With INVO BioScience Stock?See More Headlines Receive INVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:INVO CUSIPN/A CIK1417926 Webwww.invobioscience.com Phone(978) 878-9505FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,030,000.00 Net Margins-459.42% Pretax Margin-265.05% Return on EquityN/A Return on Assets-88.87% Debt Debt-to-Equity Ratio2.94 Current Ratio0.15 Quick Ratio0.12 Sales & Book Value Annual Sales$3.02 million Price / Sales0.97 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-0.52Miscellaneous Outstanding Shares2,740,000Free Float2,647,000Market Cap$2.93 million OptionableNo Data Beta1.45 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Steven M. Shum (Age 53)CEO & Director Comp: $260kMr. Andrea Goren (Age 57)Chief Financial Officer Comp: $215kMr. Michael Jos. Campbell (Age 66)COO & VP of Business Development Comp: $220kMr. Bojan Mitrovic Ph.D.Director of Sales USMr. Robert Joseph Bowdring Jr. (Age 66)Treasurer & Secretary Ms. Terah KrigsvoldControllerMore ExecutivesKey CompetitorsMinerva SurgicalNASDAQ:UTRSProSomnusNASDAQ:OSAG Medical InnovationsNASDAQ:GMVDFAethlon MedicalNASDAQ:AEMDProSomnusNASDAQ:OSAPView All Competitors INVO Stock Analysis - Frequently Asked Questions How have INVO shares performed in 2024? INVO Bioscience's stock was trading at $1.35 at the beginning of 2024. Since then, INVO stock has decreased by 27.4% and is now trading at $0.9801. View the best growth stocks for 2024 here. Are investors shorting INVO Bioscience? INVO Bioscience saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 12,100 shares, an increase of 10.0% from the March 15th total of 11,000 shares. Based on an average daily volume of 27,500 shares, the short-interest ratio is presently 0.4 days. Approximately 0.5% of the shares of the company are sold short. View INVO Bioscience's Short Interest. When is INVO Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our INVO earnings forecast. How were INVO Bioscience's earnings last quarter? INVO Bioscience, Inc. (NASDAQ:INVO) posted its quarterly earnings results on Monday, November, 15th. The company reported ($4.80) EPS for the quarter, missing the consensus estimate of ($4.00) by $0.80. The firm earned $0.22 million during the quarter, compared to analysts' expectations of $0.25 million. During the same quarter last year, the company earned ($7.20) earnings per share. When did INVO Bioscience's stock split? INVO Bioscience's stock reverse split on the morning of Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of INVO Bioscience? Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INVO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
